Skip to content

Study · Non-randomized trial · n = 10 · 1992

4 results

The effect of genetically engineered glucagon on glucose recovery after hypoglycaemia in man.

Hvidberg A, Jørgensen S, Hilsted J

British journal of clinical pharmacology1 Dec 1992Cited by 5 (Europe PMC)

PMID1493086 (opens in a new tab)PMCIDPMC1381458 (opens in a new tab)DOI10.1111/j.1365-2125.1992.tb05660.x (opens in a new tab)PepBankPUB-01493086
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy subjects after induced hypoglycaemia, genetically engineered glucagon increased plasma glucose as rapidly as pancreatic-extracted glucagon.

    In plain wordsIn healthy subjects, engineered and extracted glucagon raised blood glucose equally rapidly after induced low blood glucose.

    Peptide
    Glucagon
    Outcome
    No significant changePlasma glucose recovery, preparation comparison
    Study

    n = 10

    Comparator
    Pancreatic-extracted glucagon
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    The two glucagon preparations induced an equally rapid increase in plasma glucose.
    2 context sentences
    Summary · context
    To compare the effect on glucose recovery after insulin-induced hypoglycaemia of intramuscular genetically engineered glucagon, intramuscular glucagon from pancreatic extraction and intravenous glucose, we examined 10 healthy subjects during blockage of glucose counterregulation with somatostatin, p…
    Summary · context
    Thirty min after a bolus injection of 0.075 iu soluble insulin per kilogram body weight the subjects received one of the following treatments: 1 mg glucagon from pancreatic extraction intramuscularly; 1 mg genetically engineered glucagon intramuscularly; and 25 g glucose intravenously, respectively.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy subjects, engineered and extracted glucagon produced equal, abrupt glucose appearance increases within 4 min.

    In plain wordsIn healthy subjects, engineered and extracted glucagon increased glucose appearance equally rapidly.

    Peptide
    Glucagon
    Outcome
    No significant changeGlucose appearance rate, preparation comparison
    Study

    n = 10

    Comparator
    Pancreatic-extracted glucagon
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · intramuscularAs given in this study (human).

    Measurements

    Time to abrupt glucose appearance increase
    ≤ 4 min
    Both glucagon preparations, intramuscular

    Source sentences

    Summary
    This was due to an abrupt (within 4 min) and equal increase in glucose appearance rate.
    2 context sentences
    Summary · context
    To compare the effect on glucose recovery after insulin-induced hypoglycaemia of intramuscular genetically engineered glucagon, intramuscular glucagon from pancreatic extraction and intravenous glucose, we examined 10 healthy subjects during blockage of glucose counterregulation with somatostatin, p…
    Summary · context
    Thirty min after a bolus injection of 0.075 iu soluble insulin per kilogram body weight the subjects received one of the following treatments: 1 mg glucagon from pancreatic extraction intramuscularly; 1 mg genetically engineered glucagon intramuscularly; and 25 g glucose intravenously, respectively.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy subjects, plasma glucose increases lasted longer after intramuscular glucagon than intravenous glucose.

    In plain wordsIn healthy subjects, injected glucagon raised blood glucose for longer than intravenous glucose.

    Peptide
    Glucagon
    Outcome
    IncreaseDuration of plasma glucose increase
    Study

    n = 10

    Comparator
    25 g intravenous glucose
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    The increases in both plasma glucose and in glucose appearance rate were far more protracted after i.m. glucagon than after i.v. glucose.
    2 context sentences
    Summary · context
    To compare the effect on glucose recovery after insulin-induced hypoglycaemia of intramuscular genetically engineered glucagon, intramuscular glucagon from pancreatic extraction and intravenous glucose, we examined 10 healthy subjects during blockage of glucose counterregulation with somatostatin, p…
    Summary · context
    Thirty min after a bolus injection of 0.075 iu soluble insulin per kilogram body weight the subjects received one of the following treatments: 1 mg glucagon from pancreatic extraction intramuscularly; 1 mg genetically engineered glucagon intramuscularly; and 25 g glucose intravenously, respectively.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy subjects, glucose appearance increases lasted longer after intramuscular glucagon than intravenous glucose.

    In plain wordsIn healthy subjects, glucagon increased glucose appearance for longer than intravenous glucose.

    Peptide
    Glucagon
    Outcome
    IncreaseDuration of glucose appearance increase
    Study

    n = 10

    Comparator
    25 g intravenous glucose
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    The increases in both plasma glucose and in glucose appearance rate were far more protracted after i.m. glucagon than after i.v. glucose.
    2 context sentences
    Summary · context
    To compare the effect on glucose recovery after insulin-induced hypoglycaemia of intramuscular genetically engineered glucagon, intramuscular glucagon from pancreatic extraction and intravenous glucose, we examined 10 healthy subjects during blockage of glucose counterregulation with somatostatin, p…
    Summary · context
    Thirty min after a bolus injection of 0.075 iu soluble insulin per kilogram body weight the subjects received one of the following treatments: 1 mg glucagon from pancreatic extraction intramuscularly; 1 mg genetically engineered glucagon intramuscularly; and 25 g glucose intravenously, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.